CurrentColorado Rocky Mountain Health PlansPolicy N/A

Erythromycin 0.5% Ophthalmic Ointment — Neonatal GON Prophylaxis (Zero Dollar Cost-Share)

Defines coverage and zero dollar cost-share authorization for erythromycin 0.5% ophthalmic ointment when used for primary prevention of gonococcal ophthalmia neonatorum (GON) in newborns; applies to members covered under the payer's pharmacy clinical programs.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyErythromycin 0.5% Ophthalmic Ointment — Neonatal GON Prophylaxis (Zero Dollar Cost-Share)

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateSep 1, 2025

Next Review DateJun 1, 2025

Key ActionObtain prior authorization for zero copay when the newborn meets coverage criteria and document intent to administer or newborn age.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

0.5%erythromycin concentration covered

up to 1 moauthorization duration

zeromember cost share

P&T through 6/2025program review history

Coverage Criteria for Erythromycin 0.5% Ophthalmic Ointment

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Zero Dollar Cost-Share Eligibility

Coverage of erythromycin 0.5% ophthalmic ointment at zero dollar cost share will be approved when ANY of the following are met:

Primary criteria: Member or health care provider intends to administer medication to newborn for the prophylaxis of gonococcal ophthalmia neonatorum

Authorization up to 1 month

Age criteria: Newborn is 0-1 month of age0-1 month

Authorization up to 1 month

None specified.

Provider Requirements and Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for zero dollar cost share for erythromycin 0.5% ophthalmic ointment when the member or provider seeks coverage that bypasses member cost-sharing. Authorization, when issued for zero copay with deductible bypass, will be valid for up to 1 month from the approval date.

Authorization duration: up to 1 month from approval

Step Therapy

Step therapy does not apply to erythromycin 0.5% ophthalmic ointment for neonatal prophylaxis. No step edits or prior trials of alternative agents are required.

Documentation Required

Required Documentation

Providers must document intent to administer the medication to the newborn and provide either a provider attestation or member attestation supporting the indication. Supporting documentation should include the newborn's date of birth (to confirm age 0–1 month) and clinical indication (prophylaxis for gonococcal ophthalmia neonatorum). Retain documentation in the medical record and submit upon request.

Required documentation: provider or member attestation of intent to administer
Supporting items: newborn date of birth; clinical indication stating prophylaxis for gonococcal ophthalmia neonatorum

Note

Eligibility Triggers

Eligibility for zero dollar cost share is triggered when the intent is to administer erythromycin 0.5% ophthalmic ointment to a newborn for prophylaxis of gonococcal ophthalmia neonatorum and the newborn is age 0–1 month. Meeting either the documented intent to administer OR confirmation that the patient is a newborn 0–1 month old satisfies the eligibility criteria for authorization of zero dollar cost share.

Eligibility triggers: intent to administer for gonococcal ophthalmia neonatorum prophylaxis; newborn age 0–1 month

Step	Requirement
1	None — no step therapy requirements for erythromycin 0.5% ophthalmic ointment

Key Definitions

GON — definition and clinical significance

DefinitionGonococcal ophthalmia neonatorum (GON): a neonatal conjunctival infection caused by Neisseria gonorrhoeae that can rapidly progress to corneal scarring, ocular perforation, and blindness within 24 hours of birth.

Clinical significanceGON can cause severe ocular damage including corneal scarring, perforation, and blindness as early as 24 hours after birth, making prompt prophylaxis critical.

Preventive recommendationUSPSTF recommends prophylactic topical ocular medication for all newborns to prevent GON.

Approved prophylactic agentErythromycin ophthalmic ointment is the only FDA‑approved drug for prophylaxis of GON.

Public health/standard of careOcular prophylaxis of newborns is mandated in most states and is considered standard neonatal care.

Background

Gonococcal ophthalmia neonatorum (GON) is an acute neonatal conjunctival infection caused by Neisseria gonorrhoeae that can rapidly progress to severe ocular damage, including corneal scarring, perforation, and blindness if not prevented. The USPSTF recommends prophylactic topical ocular medication for all newborns to prevent GON, and most states mandate ocular prophylaxis as standard neonatal care. Erythromycin ophthalmic ointment 0.5% is the only FDA‑approved agent for GON prophylaxis and is the agent covered under this policy.

This policy authorizes erythromycin ophthalmic ointment 0.5% at a zero dollar cost share when the intention is primary prevention of GON in a newborn (including administration at birth or within the first month of life). Prior authorization for the zero dollar cost share will be issued when the newborn meets the listed criteria, and authorizations are issued for up to 1 month from approval. Providers should retain documentation or attestation that the medication will be used for prophylaxis of GON or that the infant’s age is within 0–1 month.